The HRT Guide: What It Does, Who It Helps, Risks, Benefits and the Shit Nobody Explains Properly

The Basic Facts

HRT and MHT are two names for the same treatment family

Menopausal hormone therapy, or MHT, is the current Australian term for what many people still call hormone replacement therapy or HRT. It uses prescribed hormones, usually oestrogen with or without a progestogen, to treat symptoms linked to the menopause transition.

There is no single product called ‘HRT’. Oestrogen can be delivered through tablets, patches, gels, sprays or local vaginal products. Progestogens come in several forms. The route, dose and combination matter because benefits, side effects and risks are not identical across every option.

The Treatment Desk

MHT is the most effective treatment for hot flushes and night sweats

Current Australian guidance describes MHT as a safe and effective treatment for many healthy people with menopause-related symptoms. It is particularly effective for hot flushes and night sweats. It may also help sleep problems or mood changes when those are tied to menopause symptoms, and it helps prevent bone loss while it is being used.

The Risk-Benefit Briefing

For many symptomatic women, the benefits outweigh the risks

The Australasian Menopause Society states that, for the majority of symptomatic women, the benefits of MHT outweigh the risks. Treatment decisions should still be individual. The conversation changes with age, symptom severity, time since menopause, personal and family history, smoking, blood pressure, migraine, clot risk and previous cancer.

MHT is commonly considered particularly favourably for healthy symptomatic women who are younger than 60 or within about 10 years of menopause. That does not create a magical birthday cliff. It means the balance of benefits and risks changes as baseline health risks change with age and time.

Anatomy Has Entered The Meeting

Whether you have a uterus changes the prescription

If you have had a total hysterectomy, oestrogen-only MHT may be appropriate. If you still have a uterus, systemic oestrogen is usually paired with a progestogen. The progestogen protects the uterine lining from the increased risk of endometrial cancer caused by unopposed systemic oestrogen.

The Delivery Department

The route matters, especially when clot risk matters

Oral and transdermal oestrogen do not behave identically. Tablets pass through the liver before reaching the wider circulation. Patches and gels deliver oestrogen through the skin. This difference matters when assessing venous thromboembolism risk.

The Headline Everyone Remembers

Breast cancer risk is real, but ‘HRT causes breast cancer’ is too crude to be useful

Breast cancer risk depends on the type and duration of systemic MHT, along with a person’s existing baseline risk. Combined oestrogen-progestogen therapy is associated with a different breast cancer risk profile from oestrogen-only therapy. The absolute increase for an individual may be small, but it should be discussed clearly rather than hidden behind either panic or cheerleading.

NICE’s current menopause guidance advises discussing how breast cancer risk varies with the type and duration of HRT. The Australasian Menopause Society similarly recommends putting the risk into individual context and balancing it against symptom burden and other benefits.

The Local News Desk

Low-dose vaginal oestrogen is not the same exposure as systemic MHT

Vaginal oestrogen is used locally for symptoms such as vaginal dryness, burning, discomfort and some urinary symptoms. It produces much lower systemic exposure than standard systemic MHT and is treated differently in guidance.

The Follow-Up File

Starting MHT should come with a review plan, not a prescription disappearing into the mist

Australian Government guidance says mild side effects can occur when starting MHT and a follow-up is commonly recommended after about 6 to 12 weeks. NICE recommends using the lowest effective dose and reviewing treatment after starting.

The Complicated Cases Desk

Some histories change the conversation. They do not justify a five-second dismissal

MHT may be unsuitable, require specialist advice or need a different formulation when certain conditions are present. Australian Government guidance highlights histories such as breast or uterine cancer, unexplained vaginal bleeding, certain heart conditions and increased blood-clot risk.

The Marketing Department Has Been Detained

‘Bioidentical’ does not automatically mean safer, and compounded products are not the premium upgrade

Many regulated prescription MHT products already contain hormones that are chemically identical to hormones produced by the body. Compounded ‘bioidentical’ hormones are custom-made products marketed as more natural or personalised. Major Australian guidance does not recommend them.

The Actual Point Of The Meeting

The right question is not ‘Is HRT good or bad?’

The useful question is whether a specific treatment offers more benefit than risk for you, at this point in your life, for the symptoms and health priorities you actually have. Shared decision-making is supposed to be a conversation, not a doctor announcing a verdict from Mount Clipboard.